Keywords: Bayer, Riociguat, Ph III, PAH, Pulmonary arterial hypertension

Bayer presents strong Ph III riociguat data, which met primary endpoint in PAH

Article | 23 October 2012

Print This

Germany’s Bayer (BAYN: DE) HealthCare unit yesterday announced positive data for riociguat from the pivotal Phase III study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in